Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer

NCT02730416 is registered in ClinicalTrials.gov with Nordic Society of Gynaecological Oncology - Clinical Trials Unit as lead sponsor.

NCT NCT02730416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02730416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer
Lead sponsor
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase
Phase 2
Overall status
Completed
Start date
December 12, 2016
Completion date
November 25, 2021
Enrollment
146 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer